Cooper Companies Shares Plunge on Revenue Miss, Weak Outlook

Shares of Cooper Companies (NYSE: COO) plummeted on Thursday after the medical device maker reported fiscal third-quarter revenue that fell short of Wall Street expectations and provided a weak outlook for its core contact lens business.

The sharp market reaction, which saw the stock drop 14.07% to $54.55, came despite an earnings beat, as investors focused on signs of slowing momentum, inventory issues, and a recently canceled strategic review of its CooperSurgical division.

Quarterly Results Miss the Mark

For its third quarter of fiscal year 2026, Cooper Companies reported mixed financial results:

• Revenue: $1.066 billion, missing the consensus estimate of $1.10 billion.
• Adjusted EPS: $1.15, slightly ahead of the $1.12 estimate.
• Organic Growth: Revenue grew only about 1% on an organic basis.

While productivity gains helped lift the company's operating margin to 26.3%, this was not enough to offset investor concerns about the top-line miss. The company also generated a record $273 million in free cash flow during the quarter.

Inventory and Strategic Concerns

Ad

Management attributed the weakness in its CooperVision segment to inventory destocking in the U.S. market, stating that the issue was not driven by a drop in underlying consumer demand. According to the company, about half of the inventory reduction was completed in Q3, with the remainder expected in the fourth quarter. However, the Q4 guidance for CooperVision, which implies organic growth between -2% and flat, has fueled investor skepticism.

Adding to the uncertainty, the company announced it would retain its CooperSurgical division after a strategic review failed to produce offers that reflected adequate value. The decision to keep the unit, which has faced competitive pressures, increases the pressure on management to improve its growth prospects.

Looking Ahead

Investors will be closely watching Cooper's fourth-quarter results, expected around December 3, for proof that the inventory issues are temporary. The company's guidance for fiscal 2027 will also be critical in demonstrating whether planned sales force expansions can reignite growth.

In response to the report, several analysts lowered their price targets on the stock, including Baird to $61 and BofA Securities to $65. While an expanded $3 billion share repurchase authorization may provide some support for the stock, the market's focus remains on the company's ability to restore organic growth momentum.